HDAC9 and central nervous system cancer: Fortunately, the finding that HDAC inhibitor tacedinaline, currently a phase II anti-cancer agent, is capable of effectively killing the TMZ-insensitive glioma cells with H2AFJ upregulation provides a feasible strategy for combating the H2AFJ-promoted TMZ resistance in clinical GBM patients.